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CHAPTER 1. INTRODUCTION
The incidence and prevalence of Type 2 diabetes (T2D) is climbing steadily across the
globe. There are approximately 425 million adults living with diabetes around the world with more
than 90% of them having T2D. This prevalence will increase to 629 million worldwide by 2045
(1). The incidence of T2D was most commonly seen in older adults; however, it has been
discovered with increasing incidence in younger adults, adolescents and children due to physical
inactivity, poor diet and increased incidence of obesity. Despite of the fact that the causes of T2D
are not been completely understood, it is revealed to be strongly related to overweight, obesity,
ethnicity, family history and increasing age. Additional but modifiable risk factors include:
prediabetes, impaired glucose tolerance, excess adiposity, poor nutrition, smoking and physical
inactivity (1). Among these factors increasing the risk of T2D, the most influential factors are
behaviors related to modern lifestyle, which include unhealthy food choices and more sedentary
lifestyle. It has been demonstrated by clinical trials that adopting healthy diet (2-4) and increasing
physical activity (5) can prevent or delay T2D.
T2D is characterized by hyperinsulinemia, insulin resistance, and pancreatic -cell failure.
T2D is generally affected by genetic and environmental factors. Recent studies have revealed
possible interactions between T2D and the gut microbiome (6, 7). It was revealed that healthy
individuals and patients with T2D had different composition of gut microbiome, specifically the
population ratio of Bacteroidetes to Firmicutes (8). In addition, a specific strain (Akkermansia
muciniphila) was reported to have a decreased abundance even prior to the incidence of diabetes
and inflammatory bowel disease (9).
Obesity is one of the major factors that contributes to the incidence of T2D by decreasing
insulin sensitivity in liver, adipose tissue, skeletal muscle and subsequently induce β-cell function
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(10). The global prevalence of obesity explains the tremendously increased incidence of T2D over
the past two decades. Obesity is characterized by low-grade chronic inflammation, and it is known
to increase the risk of life-threatening diseases including diabetes, cardiovascular diseases, and
nonalcoholic fatty liver disease. Over 600 million people are suffering from obesity and its related
comorbidities (11).
The understanding of obesity etiology and developing effective prevention and treatment
strategies have been challenging due to various contributing risk factors. Obesity occurs mainly
due to unregulated balance between energy intake and expenditure. Increasingly researches have
been focused on the regulation of energy balance, including biological, behavioral and
environmental interactions from the point of human gut microbiome (12). To reverse the
consequence of caloric imbalance, lifestyle intervention has been a focus for its potential benefits.
In general, individuals with modified behaviors achieved effective weight loss of 5% – 10% for
up to 12 months (13). In addition, the association between obesity and gut microbiome in both
mouse and human studies have shown evidence that obesity is associated with altered relative
abundance of gut microbiota diversity, such that a higher capacity for harvesting energy from the
diet was observed in obese individuals (8). Recent studies have shown evidence that gut microbiota
has a causal role in energy balance, obesity development and associated metabolic dysfunctions
(14).
Gut microbiota
The human microbiome is a complicated and dynamic ecosystem, which contains trillions
of microbes. It is considered a “hidden organ” due to its inhabiting microbes (15) and accounts for
approximately 1 kg of body weight (16). It has effects on nutrient absorption, metabolism,
immunologic regulation and pathogen resistance (17, 18). Human gut is initially colonized by
bacteria starting from the mother and the surrounding environment from the moment of birth.
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Factors contributing to the composition of gut microbiota include infant delivery methods, mode
of feeding, antibiotic treatment and environment hygiene. In the first year of age, the infant
gastrointestinal tract (GIT) develops extremely dense microbial colonization when influenced by
factors including host genotype, gut environment changes and the introduction of solid foods (19).
The gut microbiota gradually shapes into a stable and more complex community at approximately
3 years of age (16). In adult individuals, gut microbiota remains relatively stable and most strains
are gut colonizers for decades. The early colonizers acquired from parents and siblings have the
most possibility to exert physiologic, metabolic and immunologic effects on the host (20). In fact,
the ecosystem of gut microbiota is modified by various factors in daily life, including diet alteration
and antibiotic exposure. Both the gut bacteria and the host receive corresponding nutrients when
various diets are introduced. According to a mouse study, it has been reported that diet alteration
accounted for approximately 57% of total structural variation in gut microbiota while genetics
explained less than 12%. Furthermore, diet might play a dominating role in shaping gut
environment into an entity which would accelerate the development of metabolic syndrome (21).
In addition to diet, antibiotic is another factor that significantly disturb the gut microbiota
ecosystem. When an individual takes a single dose of an oral antibiotic, it takes the gut microbiota
approximately four weeks to resemble the pre-treatment status while some species need
significantly longer time such as six months. Repeated antibiotic exposure may also induce a
diversity alteration that gut microbiota would not be able to recover to its original status ever.
Instead of recovering, it shifts into a new stabilized but altered composition (18, 22).
Evidence showed that healthy adults share most bacterial species, which constitute the
concept of “core microbiota”. On the other hand, culture-independent sequencing researches
demonstrated a vast gut microbial diversity over time and across populations. There are more than
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a thousand species-level phylotypes in an adult, while most of them belong to a limited number of
phyla (15). The two major bacteria divisions that most phylotypes belong to are Bacteroidetes and
Firmicutes, fewer phylotypes are members of Actinobacteria, Proteobacteria, Fusobacteria and
Verrucomicrobia phyla (23), and others belong to methanogenic archaea, eukarya and viruses (15).
Over the last few decades, the discovery of the composition and functions of the human
gut microbiota has increased enormously. The composition of gut microbiota varies depending on
pH, temperature, oxygen tension, redox potential, water activity, salinity and light (24). The gut
microbiota mainly colonizes in the colon where no digestive enzymes are secreted to process
indigestible macronutrients from the ileum. With gut microbial metabolism, oligosaccharides and
polysaccharides are processed into short chain fatty acids, and phenolic compounds are processed
into bioactive compounds (25). Backhead et al. discovered that the alteration of gut microbiota in
germ-free mice with microbiota achieved from conventionally raised, genetically obese mice
resulted in an increase of 60% of body fat, and development of insulin resistance in two weeks
regardless of a decreased consumption by 29% and an increased activity by 27% when compared
to germ-free mice whose gut microbiota composition was not altered (26). Based on these findings
in animal studies, clinical trials have been conducted to study the differences of microbiota in the
human gut. It was reported that the overweight/obese and lean individuals showed substantial
differences in intestinal microbiota composition and their functions, which including decreased
microbial richness and increased pro-inflammatory microbial species related to low-grade
inflammation and insulin resistance (27, 28). The major contribution of gut microbiota to the host
is to prevent the colonization of potential pathogenic microorganisms, including outcompeting
invading ecological niches and metabolic substances from pathogens. In addition, gut microbial
metabolites are providing up to 50% of the daily energy requirements for colonocytes, which is
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mainly butyrate by fermenting carbohydrates into organic acids. The gut microbiota also play an
important role in modulating the host immune system, not only affecting new-borns but also
healthy adults (29). In fact, the benefits of gut microbiota can be easily overcome by
gastrointestinal infection, chemotherapy and chronic diseases such as inflammatory bowel disease
and colon cancer (29).
Probiotics
The concept of probiotic was first described as “substances secreted by one microorganism
which stimulates the growth of another” by Lilly and Stillwell in 1965 (30). In the following two
decades, the definition of “probiotic” has been continuously revised by Fuller (31) and Havenaar
et al. (32). The current internationally accepted definition was refined by Guarner and Schaafsma,
which is “living microorganisms, which upon ingestion in certain numbers, exert health benefits
to the host beyond inherent basic nutrition”(33). In Expert Panel 2001, the Food and Agriculture
Organization of the United Nations and the WHO (FAO/WHO) gave probiotics the definition as,
“living microorganisms that, when administered in adequate amounts, confer a health benefit on
the host”, which has been most widely adopted and accepted worldwide since then. In the
following year, FAO/WHO Working Group produced guidelines to help with interpretation of the
original document (34).
The effects of probiotics cannot be generalized since the effects are very strain specific.
And a single probiotic strain might present various benefits when used in combination or used
individually. The benefits may also vary when used among different individuals (35).
Bifidobacterium, Lactobacillus and Saccharomyces are extensively studied and commonly used
as probiotics in humans and animals (36). Dairy products are the most widely distributed products
containing Lactobacillus and Bifidobacteria, which has made consumers worldwide aware of the
concept of “probiotics”. Some of the benefits of dairy probiotics have been extensively studied,
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such as reducing antibiotic-associated diarrhea (37), relieving seasonal allergies (38), improving
symptoms of inflammatory bowel diseases (39), shortening duration of acute respiratory infections
in healthy children and adults(40), and lowering blood cholesterol in hypercholesterolaemic adults
(41).
Probiotics can interact with the host in multiple ways, which include inhibiting pathogenic
effects by producing bactericidal substances to compete with pathogens and toxins for adhering to
intestinal epithelial layer; improving epithelial homeostasis by enhancing barrier function,
promoting intestinal epithelial cell survival and stimulating epithelial protective responses;
promoting immune system by modulating innate immunity and controlling pathogen-induced
inflammation (36).
Prebiotics
In addition to probiotics that are beneficial to host health, prebiotics are supplemented to
boost effects of probiotics. Prebiotics was first defined by Gibson as non-digestible food
ingredients that can benefit the host health by selectively stimulating the growth and/or activity of
one single bacterium or a limited number of bacteria in the colon. A food ingredient can be
categorized as a prebiotic when it meets all the following requirement: Can be neither hydrolyzed
nor absorbed in upper part of GIT; be a selective substrate for one bacteria or a limited number of
beneficial bacteria commensal in the colon, which are stimulated to grow and/or are metabolically
activated; has the ability to alter colonic microbiota by favoring a healthier composition; be able
to induce luminal or systematic improvement on host health. The potential categories of prebiotics
include non-digestible carbohydrates, peptides and proteins, and lipids (42).
In 2016, the International Scientific Association for Probiotics and Prebiotics (ISAPP)
updated the definition of prebiotic as: a substrate that is selectively utilized by host microorganisms and confers a health benefit (43). Ingredients that have been reported with
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gastrointestinal health benefit include non-digestible oligosaccharides (NDO), human milk
oligosaccharides, and soluble fermentable fibers. NDO are carbohydrates with low molecular
weight in-between simple sugars and polysaccharides (44), and the most studied NDO are
galactooligosaccharides (GOS), fructooligosaccharides (FOS) and inulin. NDO have been used
widely since 1980 for modifying emulsification capacity, gel formation, viscosity, freezing point
and coloring in food industry. In addition, NDO show beneficial properties such as moderate
sweetness, low calorimetric value and low glycemic index. Dietary fibers cannot be digested by
human enzymes but can be fermented by microbes in the GIT. Common substances produced from
fermentation are lactic acid, hydrogen, methane, carbon dioxide and short-chain fatty acids
including acetate, propionate and butyrate. They are able to increase fecal weight and defecation
frequency, to relieve constipation and improve the health of large intestine mucus layers (45).
Numerous studies have focused on improving gut microbial ecosystem using prebiotics by
modification of bifidobacterial and lactobacilli colonization (46). Evidence showed that
supplementation of prebiotics (a GOS and FOS combination) was associated with reducing early
occurrences of atopic dermatitis in infants (47); decreasing incidence of atopic eczema in six month
old infants (48); relief of symptoms associated with intestinal bowel disorders and providing
positive effects on lowering risk of colon cancer (49); and improving immune responses in elderly
people (50).
Food companies started to add prebiotics into probiotic foods in the market, then the term
“synbiotic” was defined. Andersson et al. gave synbiotics the definition as: mixtures of probiotics
and prebiotics that beneficially affect the host by improving the survival and implantation of live
microbial dietary supplements in the GIT of the host (51). Studies have shown evidencs that
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synbiotics are beneficial for immune system, which include reducing C-reactive protein levels,
increasing glutathione levels (52), and suppressing intestinal and systemic inflammation (53).
Akkermansia muciniphila
The probiotic this study focused on was Akkermansia muciniphila (A. muciniphila). The
name Akkermansia was derived from a Dutch microbiologist Antoon Akkermansia for his
contribution to the study of microbial ecology. Muciniphila was named after its preference of
mucin as an important nutrient. The A. muciniphila cells are non-motile, Gram-negative and ovalshaped. The reason for limited studies on A. muciniphila is the characteristics of strictly anaerobic.
Growth of A. muciniphila occurs at temperature of 20 - 40 °C with pH 5.5 - 8.0. It is able to grow
on brain-heart infusion, Columbia media, and gastric mucin. A. muciniphila has the ability to use
mucin as carbon, nitrogen and energy source (54). It is the first isolated intestinal microbial of the
Verrucomicrobia phyla (55). It was suggested by Derrien et al that A. muciniphila had a higher
abundance in the colon than in the ileum, both in mono-colonized and conventionally raised mice
(56, 57). The development of A. muciniphila in human with different demographics and at various
life stages was investigated by Carmen et al.. A. muciniphila was detected in the GIT of 1-month
old infants and it takes less than one year to reach the abundance level of 108 cells/g as in adults
while the level decreases significantly (1 logarithmic unit) in elderly subjects (58).
Several clinical studies have been done to reveal abundance of A. muciniphila among
different target population. Results showed that there is a negative correlation between A.
muciniphila abundance and BMI, both in children and adults (59-61). Interventions such as weight
loss and calorie restriction were able to increase A. muciniphila prevalence significantly (62, 63).
Dietary ingredients were tested for their benefits on A. muciniphila population and relevant
improvement on host health status. These ingredients included as FOS (64, 65), oat bran(66), black
tea extracted polyphenols (67), grape pomace polyphenols (68), and cranberry polyphenols (69).
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With all the potential health benefits, food manufacturers have been promoting food
products containing probiotics and/or prebiotics. However, before largescale production can be
achieved, the characteristics of probiotics and optimal culturing conditions should be defined. At
the present time, there is not much research that has been conducted in these areas. Therefore, the
current research was conducted to collect this information.
Specific aims
The objective of the current study was to improve the growth and survivability of A.
muciniphila in GIT conditions and to further examine the long term (6-month) dietary effect of A.
muciniphila supplementation on high-fat diet induced obesity and diabetes in C57BL/6 mice.
Aim 1
The first aim was to optimize the growing conditions of A. muciniphila, such as
temperature, pH and prebiotics. These would subsequently be used in improving techniques to
overcome the issue of culturing difficulties. It is hypothesized that alternative carbohydrate source
other than dextrose could also be used as a part of growth medium that may improve the optimal
growth condition and eliminate adverse effects on host glucose homeostasis. The selected
prebiotics could be incorporated as synbtiotic to further bring out potential benefits.
Aim 2
Aim 2 was to improve sustainability of A. muciniphila in GIT by developing new coating
technology. From the evaluated properties of A. muciniphila, additional obstacles such as adverse
environmental conditions from human GIT would be investigated to discover the the ability of A.
muciniphila to tolerate stressed conditions. Specifically, the significant impact on cell viability
from human GIT such as the acidic stomach environment and the drastic change in pH post
stomach digestion with the digestive enzymes would be examined. The improvement of
encapsulation was hypothesized to enhance cell viability throughout the passage of GIT where
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harsh environment would significantly diminish cell count post digestion without encapsulation.
Thus, various frequently used encapsulation methods would be evaluated to determine the
potential optimal technique in protecting A. muciniphila viability and availability. The optimal
encapsulation method would ensure the delivery of coated A. muciniphila cell through GIT
digestion with minimal loss of viability and consequently reaching favorable condition in the large
intestines.
Aim 3
Aim 3 was to determine long term effect of A. muciniphila dietary supplementation on
high-fat diet induced obesity and diabetes. Continuous supplementation of A. muciniphila was
hypothesized to maintain C57BL/6 mice glucose homeostasis, reduce body weight and improve
body composition. It was expected that high-fat fed mice treated with A. muciniphila would
maintain consistent weight gain similar to that of mice fed the control low-fat diet, and maintain
normal fasting glucose levels via an altered energy absorption. This aim would focus on evaluating
potential beneficial effects of A. muciniphila supplementation in order to improve the
understanding of its sustainability and dosage effect over long time of supplementation.
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CHAPTER 2. OPTIMIZATION OF

THE GROWTH

CONDITIONS FOR

A.

MUCINIPHILA
The determination of optimal growth condition is fundamental but critical because the
information will be used to further enhance culturing techniques, optimize manufacturing
processes, determine storage methods and evaluate the necessity of additional protection for
delivering through human GIT. Temperature and pH are the two most important factors for
growing microorganisms; therefore, tests were designed to determine the optimal temperature and
pH for supporting the optimal growth of A. muciniphila within tolerable ranges of temperature and
pH. To stimulate the growth of A. muciniphila as a probiotic, several well-known prebiotic
ingredients were compared as part of growth media to create a potentially superior synbiotic
formula. After achieving an optimal growth condition for A. muciniphila on a small scale, the next
test was set to find the proper and cost-efficient media supplement for manufacturing A.
muciniphila for achieving a larger quantity, which could be further utilized when preparing A.
muciniphila culture for mouse studies and human clinical trials.
In animals and humans, most of the gut microbiota confronts large amounts of bile salts.
Bile acids are synthesized mainly from cholesterol in the liver, conjugated with taurine or glycine,
stored in gall bladder and released into duodenum upon the need in fatty acid digestion. The
presence of bile salts is continuous through enterohepatic circulation (70). Besides the fact that
bile salts are natural emulsifiers in the intestines, they also function as a microbial detergent. Some
microorganisms possess the ability to modify bile salts biochemically to resist the detergent
property. Therefore, bile salt tolerance (carried out by bile salt hydrolase (BSH) activity) is
desirable for probiotics (71). In the small intestine, microbial bile salt hydrolase produces
unconjugated bile acids by removing taurine or glycine molecules (72). Released bile acids are
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absorbed back to the enterohepatic portal system via terminal ileum, while part of them enters
large intestine to be metabolized into secondary and tertiary bile acids (73). These freed bile acids
are less soluble thus less are reabsorbed by intestinal lumen when compared to conjugated bile
acids. Consequently, these free bile acids are excreted in feces from human body. This could
promote higher metabolism of cholesterol and lower serum cholesterol subsequently. Based on
this mechanism, the deconjugation of bile salts by BSH is ubiquitous within healthy gut microbiota
(74, 75). Probiotics with BSH activity have been proved to improve LDL-cholesterol and
subsequently bile acids level in clinical study (75). A few microorganisms have been discovered
with BSH activities, such as Bifidobacterium spp., Lactobacillus spp., Bacteroides fragilis subsp.
fragilis, Enterococcus spp., Clostridium perfringens, and Listeria monocytogenes (70, 76, 77).
Inspired by discovery of BSH activity in probiotics like Bifidobacterium spp., Lactobacillus spp,
BSH activity of A. muciniphila was an evaluation objective for its potential benefits to the host
health in the current study.
In addition to discovery of optimum culture and manufacture conditions and potential BSH
activity of A. muciniphila, the last aim was to evaluate the efficacy of proper storage method for
maintaining viability of A. muciniphila during short and long-term storage.
Methods
Anaerobic culture medium preparation
Dehydrated Brain-heart Infusion (BHI) medium (Bioworld, Dublin, OH) was dissolved in
distilled water with concentration of 37 g/L and 0.1% w/v resazurin solution (Thermofisher Acros
Organics, Morris Plains, NJ) was supplemented afterwards in the medium. After boiling, BHI
medium was cooled to room temperature while sparging with 100% nitrogen, then dispensed into
anoxic Hungate-type tubes with a volume of 10 mL each under the same gas atmosphere. Filled
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hungate tubes were then autoclaved at 121 °C for 15 min, cooled to room temperature, and stored
at 4 °C for further culture if not used immediately.
Resuspension and culture of A. muciniphila
The procedure of resuspension and culturing requires to be under oxygen-free environment.
The purchased A. muciniphila came in a double-layered vacuum ampoule. One cannula was
prepared to supply nitrogen to the ampoule containing freeze-dried A. muciniphila powder. With
gassing cannula inserted in the ampoule, 0.5 mL of BHI medium was added to the vial and the cell
pellet was resuspended completely. The cell suspension was transferred into a prepared hungate
tube using a 1 mL syringe with hypodermic needle, which was also flushed with nitrogen. It is
possible that certain ingredients of the freeze-dried pellet might inhibit growth in the first hungate
tube, therefore additional two hungate tubes were used to make diluted culture of 1:10 and 1:100
in order to guarantee successful resuscitation.
Handling and transferring of actively growing A. muciniphila cultures
When culturing A. muciniphila in small quantity, hungate tubes were used to culture and
transfer at all times. The surface of hungate tube cap had to be sanitized before and after inoculation
and transfer. The butyl rubber septum and screw cap were sterilized over flaming. Since microbial
growth induces overpressure in hungate tubes, excess gas was removed by puncturing the septum
with a sterile injection needle. Then a sterile anoxic, disposable 1 mL syringe with a 25 G
hypodermic needle was used to withdraw and transfer cultures.
Strain verification
Contamination quick screening
Gram staining technique was used for quick screening of cross-species contamination. A.
muciniphila culture sample was heat-fixed on slide, then stained as manufacturer instructed.
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Stained slides were viewed under light-microscope (Fisher scientific, Hampton, NH) with oilimmersion at 100/1.25 lens to check color and shape of cells.
General PCR verification
DNA of A. muciniphila sample was extracted using QIAamp DNA Mini Kit (Qiagen,
Germantown, MD) according to manufacturer’s instructions. Extracted DNA was stored at – 20 °C
for future tests. Two specific primers were used to verify the sample DNA, 16s rDNA forward
primer: 5’ CAG CAC GTG AAG GTG GGG AC 3’, 16s rDNA reverse primer: 5’ CCT TGC GGT
TGG CTT CAG AT 3’ (78). The PCR mixture was prepared with final volume of 25 μL, which
contained 12.5 μL of 2 x PCR Sigma ReadyMix RedTaq PCR Reaction Mix (Sigma-Aldrich, St.
Louis, MO), 0.1 μM forward primer, 0.1 μM reverse primer, 2 μL template DNA, 8.5 μL nucleasefree water. Eppendorf Mastercycler EP S Thermal Cycler (Eppendorf, Hamburg, Germany) was
used to for PCR with procedure of initial denaturation at 95 °C for 5 minutes, followed by 40
cycles of denaturation at 95 °C for 15 seconds, primer annealing at 60 °C for 40 seconds, extension
at 72 °C for 30 seconds, and final extension at 72 °C for 5 minutes. 1.5% agarose gel was prepared
with 1 x Tris-Borate-EDTA (TBE) buffer for gel electrophoresis. PCR product was compared to
low range DNA ladder with range 25 – 700 bp (Thermo Fisher Scientific, Ann Arbor, MI). The
gel containing separated PCR products was visualized by SYBR Green staining under Bio-rad
Imager (Bio-rad, Hercules, CA).
Turbidity verification
Fresh A. muciniphila culture was used from the original A. muciniphila stock, then a tenfold serial dilution was made. Duplicated hungate tubes were prepared for each diluted
concentration. A. muciniphila original culture and all diluted cultures were incubated at 37 °C for
10 hours. 500 μL of each culture was transferred using an anoxic syringe into 48-well plate and
optical density (OD) values were measured at 595 nm using Epoch 2 spectrophotometer (Biotek,
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Winooski, VT). At the same time, each diluted culture was tested for colony forming unit (CFU)
using pour-plating technique with ten-fold dilution (79). BHI agar was prepared by dissolving 1.6 %
agar and 3.7 % BHI medium in distilled water. 10 μL of each dilution was pipetted onto the bottom
of petri dish (60mm x 15mm), then 15 mL BHI agar was poured into the petri dish and swirled for
even distribution. All petri dishes were placed in anaerobic jar for 24 hours at 37 °C. Standard
curve was established based on OD values and their corresponding CFU/mL.
Exponential growth rate calculation
Growth curve under each condition was established with OD values at each time point.
Based on the equation achieved by turbidity verification, CFU of each time point could be
determined by corresponding OD value. The first step was to identify the start and end points of
exponential phase based on the growth curve. The following formula was adopted to calculate
growth rate. X0 implies the initial CFU, Xt implies the final CFU and “log” is the logarithm of the
base (80).
Growth rategeneration/hour =

2.303 (logXt − logX0 )
Duration time (hour)

Optimal and tolerable temperature test
Fresh A. muciniphila culture was used as original culture stock, from which 0.1 mL was
inoculated into each anaerobic BHI tube. Duplicate hungate tubes were cultured for testing under
each temperature. Then each sets of tubes were incubated for 10 hours in incubators with
temperature set up to 25 °C, 35 °C, 37 °C, 40 °C, 43 °C and 46 °C respectively. 500 μL of A.
muciniphila culture was transferred from each hungate tube into 48-well microplate using anoxic
syringe and OD values were measured at 595 nm at hourly interval. Consequent growth curves,
growth rate and final viabilities were generated and calculated.
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Optimal and tolerable pH test
After hungate tubes were filled with 10 mL BHI medium, pH value was adjusted to 2, 3,
4, 5, 6, 6.5, 7, 7.5, 8, 9 with Na2CO3 and HCl using pH meter (Oakton, Vernon Hills, IL). Duplicate
hungate tubes were cultured for testing at each pH level. All tubes were purged with nitrogen,
autoclaved and cooled down to room temperature before inoculation. Actively growing A.
muciniphila was used as the original A. muciniphila stock, then each hungate tube prepared of
varied pH value was inoculated with 0.1 mL of original A. muciniphila stock. All tubes were
incubated for 10 hours at 37 °C in incubator. 500 μL of A. muciniphila culture was transferred
using anoxic syringe from each hungate tube into 48-well and OD values were measured at 595
nm. Consequent growth curves, growth rate and final viabilities were generated and calculated.
Prebiotics selection
Duplicate hungate tubes were used for testing with each prebiotic. After filled with 10 mL
BHI without dextrose medium, each hungate tube was supplemented with 0.2% w/v prebiotic
ingredients including: isomaltooligosaccharide (IMO), inulin (INU), fructooligosaccharide (FOS),
galactooligosaccharide (GOS), guar gum (GG), acacia gum (AG), karaya gum (KG), tragacanth
gum (81), and potato starch (PS). All tubes were purged with nitrogen, autoclaved and cooled
down to room temperature before inoculating. Actively growing A. muciniphila culture was used
as the original A. muciniphila stock, then each supplemented hungate tube was inoculated with 0.1
mL of orginal A. muciniphila stock. 500 μL of each culture was transferred by anoxic syringe into
48-well plate, and the plate was incubated at 37 °C for 10 hours. OD values were measured at 595
nm every 30 min after a 5-second orbital swirl for the most consistent reading. Subsequent growth
curves, growth rate and final viabilities were generated and calculated.
Prebiotic ingredients were purchased from the following companies. GG: Bulk
supplements.com, Henderson, NV; IMO: FiberYum, Hawthorne, NY; INU and TG: MP
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Biomedicals, Solon, OH; FOS and GOS: Quantum Hi-Tech Biological Company, Guangzhou,
China; AG: Heather’s Tummy Fiber, Seattle, Washington; KG: Alfa Aesar, Haverhill, MS; PS:
Bob’s Red Mill, Milwaukie, OR.
Upscale supplement selection
The 0.2% w/v dextrose was replaced using five different sugars with the same
concentration. The supplement options included fructose, galactose, lactose, sucrose and maltose.
Same volume of A. muciniphila was inoculated into each medium and incubated at 37 °C for 10
hours. Consequent growth curves, growth rate and final viabilities were generated and calculated.
After the best three supplement ingredients were selected, the next step was to explore the
concentration that favored the growth of A. muciniphila most. The concentration levels being
tested were adjusted to 0.1%, 0.2%, 0.5%, 1% and 2%. Procedure was the same as sugar selection.
Final viabilities were calculated and compared.
Quantitative bile salt hydrolase activity
BSH activity was determined by measuring the amount of amino acid released from
conjugated bile salts by selected probiotics (82). A. muciniphila culture pellet was collected by
centrifugation and transferred into 2 mL microtubes. PBS (pH 7.4) buffer was used twice to wash
off BHI medium from A. muciniphila culture collect at centrifuge speed of 12,000 rpm for 1 minute.
Supernatant from washing was discarded after centrifuge, then the pellet was resuspended with
100 μL of PBS buffer and 100 μL of 1% bile salts (LP0055 OXOID, Ontario, Canada) and was
incubated at 37 °C for 75 minutes. After being centrifuged at 13,000 rpm for 5 minutes, 100 μL
supernatant was transferred into 1.5 mL microtube and 400 μL of 2% ninhydrin was added.
Microtubes were heated for 2 minutes in a 90 °C waterbath, and subsequently OD values of all
culture were measured at 570 nm. One unit of BSH activity (U/g) was defined as the amount of
enzyme liberating 1mmol of amino acid from the substrate in one minute. The concentration of
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protein was measured using Bradford method with albumin as standard (Thermo Fisher Scientific,
Ann Arbor, MI). In addition to A. muciniphila, another four probiotic strains were prepared with
the same steps as comparisons to A. muciniphila. The strains included Lactobacillus acidophilus
(Swanson, Fargo, ND), Lactobacillus reuteri (Nature’s Bounty, Bohemia, NY), Lactobacillus
plantarum (Swanson, Fargo, ND) and Bacillus coagulans (Sundown Naturals, Bohemia, NY). All
samples were triplicated in this study.
Storage test
Storage glycerol solution (50% v/v) was autoclaved and stored at 4 °C for future use. A.
muciniphila culture was centrifuged, and the pellet was suspended with sterile 50% glycerol
solution with a ratio of 1:1. The A. muciniphila glycerol mixture was transferred into microtubes,
flash frozen with liquid nitrogen and stored at - 80 °C. Frozen A. muciniphila glycerol mixture was
tested for CFU after 1-month, 2-month and 6-month of storage.
Statistics
Data were expressed as mean ± SD. Statistical analysis was performed using one-way
analysis of variance (ANOVA) with a Tukey post-hoc test using GraphPad Prism version 6.00 for
Windows (GraphPad Software, San Diego, CA). Results were considered statistically significant
at p < 0.05.
Results
Verification of strain A. muciniphila was performed using PCR and gel electrophoresis
imaging. The band appeared with 327 bp was considered as positive result. The verified A.
muciniphila culture was used for all further tests.
The correlation of A. muciniphila culture OD value and its corresponding CFU was
established as the following equation: 𝑦 = 1𝐸 + 07 𝑥 1.2956 (Figure 1).
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Figure 2 presented the growth of A. muciniphila during an incubation time of 10 hours by
showing its growth curve at temperature 25, 35, 37, 40, 43 and 46 °C. These growth curves showed
that temperatures ranging from 35 °C to 43 °C had similar growth curves while 46 °C reduced cell
growth and cells barely grew under 25 °C. Growth rate (Figure 3) of cells incubated at 35 °C,
37 °C, 40 °C and 43 °C showed no significant difference. Growth rate at 46 °C was at an
intermediate level, which was not significantly different from growth rates at all other temperatures.
Growth rate at 25 °C was significantly slowed down when compared to 35 °C and 37 °C (p < 0.05),
while no difference was found when compared to growth rates at 43 °C and 46 °C. Figure 4
presented the effects of temperature on final culture viability (CFU x 10 6/mL) of A. muciniphila.
Viabilities were similar at 35 °C, 37 °C and 40 °C while viabilities at 43 °C and 46 °C was
significantly lower when comparing to 37 °C (p < 0.05). 25 °C supported the growth of A.
muciniphila at the lowest level, whose viability was significantly less than viabilities at all other
temperatures (p < 0.0001).
Growth curves of A. muciniphila in BHI medium with adjusted pH level of 2, 3, 4, 5, 6,
6.5, 7, 8 and 9 at 37 °C during an incubation time of 12 hours were presented in Figure 5. The
results showed that pH 6.5 was the best pH promoting growth of A. muciniphila, followed by pH
6, pH 7 and pH 7.5. Further calculation confirmed that pH 6.5 was the best pH level with the fastest
growth rate (Figure 6), which was significantly faster than growth rates at any other temperature
(p < 0.0001). Growth rates at pH 6, 7 and 7.5 were at similar level ranging with no significant
difference among these three levels. Growth of A. muciniphila at pH 4 and pH 5 were significantly
slower when compared to pH 6.5 (p < 0.0001) while nearly no growth was detected in medium
adjusted to pH 2, 3, 8 and 9. The final viability of A. muciniphila at each pH level was presented
in Figure 7. Medium with pH adjusted to 6.5 promoted the highest final viability, which was
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significantly higher when compared to the cells grew under all other pH levels (p < 0.0001).
Medium with pH level at 6 and 7 showed final viabilities at a similar level with no significant
difference. The viability at pH 7.5 was significantly lower than the viability at pH 7 (p < 0.01) and
the viability dropped to around 4  106 CFU/mL in medium at pH 5. Medium with pH adjusted to
2, 3 and 4 was not able to promote the growth of A. muciniphila, whose final viabilities were
around half of the viability in medium with pH 5. Growth in medium adjusted to 8 and 9 was
shown with the least viability, which was significantly lower than viabilities at all other pH levels
(p < 0.0001)
The effects of prebiotics on growth of A. muciniphila was presented as Figure 8. IMO and
GOS had the best two growth curves among the nine selected prebiotics. In comparison, medium
with GG, FOS, INU, AG, KG and TG resulted in reduced cell growth while PS was shown with
the least growth of A. muciniphila. Further calculation of growth rate (Figure 9) showed that all
nine prebiotics were able to promote the growth of at a similar growth rate with no significant
difference. There was no difference found when compared the growth rates in medium adjusted
with prebiotics to medium with dextrose, except for PS (p < 0.05). Figure 10 presented the final
viabilities of A. muciniphila in medium modified with each prebiotic. IMO promoted the highest
viability, which was significantly higher than GOS as the second highest (p < 0.05). FOS, GG, AG
and INU showed approximately half viabilities of IMO while KG and TG had comparable final
viabilities as BHI medium with no dextrose. PS showed a significantly lower level of viability
comparing to all other prebiotics (p < 0.0001).
Figure 11 presented the effects of sugars on growth of A. muciniphila. There were four
candidates showing similar growth curves, which were fructose, dextrose, sucrose and lactose.
Fructose and dextrose had same sharp exponential phase, and sucrose had similar OD value as
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fructose during lag phase. A. muciniphila cultured in lactose medium showed longer time in
exponential phase with lower final viability when compared to cultures in fructose, sucrose and
dextrose medium. Maltose medium was able to support the growth of A. muciniphila, which
presented a good exponential slope while the final OD value was less than half of values measured
in top four sugar media. Culture in galactose medium revealed nearly the same growth curve as
control, which was BHI medium without dextrose. Calculation of growth rate (Figure 12) reported
that growth rates of A. muciniphila in fructose, sucrose and maltose reached to a similar growth
rate as in dextrose with no significant difference noted. Growth in lactose and galactose was
significantly slower than the growth in fructose and dextrose (p < 0.01). The final cell viabilities
suggested that A. muciniphila achieved the highest viability in medium fortified with fructose,
which was significantly higher than that in dextrose (p < 0.05). The second highest viability was
observed in sucrose, which promoted the viability of A. muciniphila with no significant difference
from the viability in dextrose. Lactose was able to promote the viability of A. muciniphila at an
intermediate level, which was significantly lower than fructose and sucrose (p < 0.05) but
significantly higher than maltose and galactose (p < 0.0001). It was clear that A. muciniphila could
grow in medium adjusted with maltose and galactose; however, the viabilities were at the same
level as in control medium with no significant difference, which were only around one third of the
viability in fructose medium (Figure 13).
The effects of sugar concentrations on A. muciniphila final culture viabilities were showed
in Figure 14. A similar trend was found among all three figures, which showed that medium with
0.5, 1.0 and 0.2% of sugar were the best three concentrations with higher level of final culture
viabilities than at other two concentrations. In medium adjusted with fructose, 0.5% fructose
showed a significantly high level of viabilities when compared to 1.0% (p < 0.01) and 0.2% (p <
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0.001). Dextrose with concentrations of 0.5% and 1.0% promoted the highest viabilities, which
were significantly better than viability achieved at concentration of 0.2% (p < 0.01). In medium
adjusted with sucrose, viabilities were similar at concentrations of 0.2, 0.5 and 1%, which were
significantly higher than at other concentrations (p < 0.01).
BSH activity of strains A. muciniphila, L. acidophilus, L. reuteri, L. plantarum and B.
coagulans were compared in
Table 1. To appropriately compare their BSH activity, all probiotics strains were adjusted
to start with a similar total protein content of approximately 356.5 (μg/mL). Results showed that
L. reuteri and L. plantarum had significantly higher BSH activity levels than all the other strains
(p < 0.0001). L. acidophilus, A. muciniphila and B. coagulans presented a similar level of BSH
activity without significant differences.
The efficiency of glycerol stock in maintaining viabilities of A. muciniphila was presented
in Figure 15. Results showed that A. muciniphila was able to be recovered successfully with less
than 0.1 Log number of viability lost after 1, 2 and 6 months of storage.
Discussion
Routine verification of A. muciniphila was tested using PCR and gel electrophoresis
imaging. Cultures with positively verified A. muciniphila were used for all further tests. Thus there
should be no concern regarding contamination of all the test samples.
In order to culture sufficient amount of A. muciniphila for discovering its characteristics
and preparing for in-vivo mouse supplementation study, it is necessary to identify the best growth
conditions for culturing A. muciniphila. Based on previous findings, A. muciniphila was able to
grow within 20 - 40 °C with pH range of 5.5-8.0 (54). The growth of bacterial can be largely
characterized by three fundamental growth constants, which are exponential growth rate, lag time
and total growth (83). Due to the shape of standard curve, the determination of lag time is difficult
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to guarantee the precision. Therefore, growth rate and final cell viability were used to determine
the optimal growth conditions for A. muciniphila. It was found that A. muciniphila was able to
growth within the temperature range of 25 – 46 °C. Based on calculated growth rates and final
viabilities, temperature from 35 – 43 °C could promote the growth with no significant difference
among the different temperatures. Temperature at or below 25 °C and temperature at or above
46 °C were not appropriate temperatures for A. muciniphila to grow. The next growth condition
being evaluated was pH tolerance range, which helps to determine optimal growing pH and also
important for exploring the survival rate of A. muciniphila under various pH environment in
GIT. To exert health benefits, dietary probiotics have to survive through GIT (stomach acids) and
colonize in the gut (84). Therefore, the growth of A. muciniphila were compared in culture medium
with adjusted pHs including pH 2, 3, 4, 5, 6, 6.5, 7, 7.5, 8, and 9. The results showed that the
optimal pH range for

culturing A.

muciniphila should

be

controlled within

6

–

7.5

where pH 6.5 was the best pH level, which was consistent with the findings from previous study
(54). The minimal cell growth at pH 2, 3, 4, 5, 8 and 9 indicated a low survival probability of A.
muciniphila when administered orally. In short conclusion, A. muciniphila showed similar growth
under a range of temperature; however, it was highly sensitive to different pH levels. Therefore,
the control of culture pH is the most critical step to guarantee the optimal growth of A. muciniphila.
The gastric pH values of healthy adults are within the range of pH 2 – 3 under fasting
conditions. While during gastric emptying procedure, pH level changes from highly acidic
environment in stomach to nearly neutral environment in duodenum (pH 6 – 6.5). In small
intestines, pH shifts gradually in different locations as well: pH value is 7.4 in terminal ileum, 5.7
in cecum and 6.7 in rectum (85). Based on these conditions and the results, the in-vivo delivery of
probiotics through stomach is critical since the strongly acidic condition would significantly
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diminish the viability of A. muciniphila. Therefore, an effective protection method is necessary
to maintain the integrity of probiotics through GIT.
Limited studies have been done to investigate proper prebiotics for promoting growth of A.
muciniphila. A previous study showed that supplementation of FOS restored the decreased A.
muciniphila population of 107/g feces back to 109/g feces induced by obesity in DIO mice (78).
Similar promoting benefit was reported by Everard et al. and Reid et al. as well (65, 86). Although
FOS has been widely investigated as a common prebiotic, there are a number of potential prebiotic
ingredients haven’t been evaluated for the strain of A. muciniphila. Therefore, nine prebiotic
ingredients including IMO, INU, FOS, GOS, GG, AG, KG, TG and PS were evaluated. To
compare the potential effects of prebiotics on A. muciniphila growth, 0.2% w/v dextrose as a
carbohydrate source in BHI medium was replaced by each of the individual prebiotic at the same
concentration and subsequently being inoculated with A. muciniphila. Based on the comparison of
exponential growth rates of A. muciniphila, it was concluded that IMO and GOS were able to
support the growth of A. muciniphila at the best efficiency when compared to all other prebiotics.
The potential factor for their superior bioavailability to A. muciniphila might be due to the simple
structures of sugar molecular composition as compared to other sugar molecules. Viabilities of A.
muciniphila in medium with other prebiotics suggested that these prebiotics were not favoring
ingredients for A. muciniphila growth, which could be explained by their long and complex
structure branch-chained with extra sugar or sugar acid units such as mannose, rhamnose and
galacturonic acid. In conclusion, IMO was the best prebiotic option in promoting growth of A.
muciniphila in regard to growth rate and final viabilities. A synbiotic formula of A. muciniphila
with IMO would be able to deliver additional viabilities and its related benefits.
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In addition to optimum growth condition in terms of temperature and pH, optimization of
cost-efficient and effective ingredients was also investigated for finding better method to promote
productivity in scaling up A. muciniphila production. According to results of prebiotics test, we’ve
demonstrated that dextrose was the best ingredient that showed the outstanding growth rate and
the highest culture viability as expected. Additionally, dextrose is less expensive as compared to
all other types of prebiotics. Inspired by this finding, six common carbohydrates were tested, which
included dextrose, galactose, lactose, fructose, sucrose and maltose. Final culture viabilities
indicated that fructose and sucrose promoted the most growth of A. muciniphila. In conclusion,
fructose was the best sugar for culturing A. muciniphila. Dextrose was another candidate that could
assure fast growth rate while sucrose was the candidate to guarantee a better culture viability.
Before starting to produce large quantity of A. muciniphila for animal study, it was
necessary to determine the optimal concentrations for the selected top three sugars. Results have
shown that 0.5% of sugar supplementation promoted the best growth of A. muciniphila, which was
significantly higher than the growth in BHI culture medium with an original sugar concentration
of 0.2%. A sugar concentration higher than 1.0% was shown to lower viability of A. muciniphila
suggesting that the osmotic pressure balance might be disturbed by higher concentration of sugar.
In conclusion, the optimal concentration for culturing A. muciniphila was 0.5% of fructose, sucrose
or dextrose.
Inspired by evidences that Lactobacillus strains having varied level of bile salt hydrolase
activity (87, 88), the BSH activity of A. muciniphila was also investigated. L. acidophilus, L.
reuteri, L. plantarum and B. coagulans were compared with A. muciniphila. L. acidophilus has
been reported to present hydrolase performance for sodium glycocholate and sodium taurocholate
in a previous study (89). B. coagulans was lately shown to have deconjugation ability on bile salts
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(90) while its BSH activity level has not been quantified. In this study, L. acidophilus, B. coagulans
and A. muciniphila were shown to have a similar level of BSH activity with no significant
difference observed among these three strains. These results indicated that A. muciniphila would
have a good survival rate due to its BSH activity, which could protect probiotics against the
detergent effects of bile salts in the gut.
Following optimizing the culturing conditions of A. muciniphila, its stability and potential
functions were evaluated as well. Before moving forward, an effective storage method had to be
evaluated and confirmed. Glycerol stock is the solution normally used for long-term bacteria
storage. To ensure A. muciniphila with reliable quality and quantity during storage, the efficiency
of 50% glycerol stock has been confirmed in this study. The viability of strictly anaerobic strain
A. muciniphila could be guaranteed with minimal loss of viability after being stored within glycerol
stock in short-term and long-term storage.
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CHAPTER 3. ENHANCE THE SUSTAINABILITY OF A. MUCINIPHILA IN GIT USING
ENCAPSULATION TECHNOLOGY
Preserving the sustainability of probiotics is extremely important to convey potential
benefits to the host. Probiotics, especially a large number of anaerobes, are fragile cells which
could be affected by a wide range of environmental factors including atmosphere, pH, temperature,
acidification during fermentation and hydrogen peroxide production. In the current market besides
capsulated supplements, probiotics are widely incorporated in dairy products. Meanwhile, the
variety of non-dairy food products is increasing rapidly as well, such as energy bars and beverages
(91). However, the survival of probiotics in those products has been reported to be low (92).
Therefore, it is important to design in vitro studies to investigate the ability of probiotic strains
survivability through harsh environment such as GI tract. Resistance to high acidity in stomach
and to high concentration of bile components in proximal intestine are critical selection criteria for
probiotics. Since Lactobacillus and Bifidobacterium have been widely incorporated in food
products, their tolerance to low pH and bile salts were extensively studied. Evidences showed that
popular strains such as Lactobacillus casei, Lactobacillus acidophilus, Bifidobacterium animalis,
Bifidobacterium lactis showed minimal survival rate under these stress factors (93). For sporeforming lactic acid producing bacteria, very few strains (Bacillus laevolacticus and most
Sporolactobacillus strains) were tolerant to acidic environment while only Bacillus racemilacticus
and Bacillus coagulans were tolerant to bile salts (94).
Based on previous evidence that most probiotic strains would lose viability in simulated
stomach and intestine conditions, protecting viable quantity and maximizing health benefits of
those probiotics have drawn extensive research interest (95). When incorporating microbial
species in foods or supplements, a functional dose is required. Health Canada accepted that when
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Bifidobacterium and/or Lactobacillus is delivered orally, the dose level should be at one billion (1
x 109) CFU per serving. The Italian Ministry of Health has regulated that the number of viable
cells administered per day should be 1 x 109 CFU minimum (34). The efficacy of added probiotic
strains depends on the dosage and the viability throughout the digestive tract after consumption.
Dairy companies have modified their formulations to ensure sufficient viability in their probiotic
products, such as using freeze-dried powders, or packaging with sachet and stick forms (96).
Nowadays, encapsulation has been used for maintaining probiotic viability in food
products. It is a process of utilizing a material or system to coat or entrap one or a mixture of
materials. The coating material is called wall material or shell and the material coated is called
core material or internal phase. The wall material is designed to protect the core material against
environmental stresses including oxygen, acidity, enzyme reactions (97). Encapsulation
techniques are utilized to produce efficient delivery vehicle to target locations within GIT, which
have been extensively utilized in food industry. The current family of encapsulation includes
emulsification, coacervation, spray-drying, freeze-drying, and extrusion (92).
Spray-drying is one of the most widely utilized encapsulation technologies in commercial
food processing. It is considered as an inexpensive, fast and consistently reproducible procedure.
The principle of the procedure is dissolving the core material in a dispersion of matrix material.
The dispersion is atomized by heated air to remove water quickly, and then separate powdered
particles at a lower temperature. The major disadvantage is the high temperature could be
detrimental to temperature and oxygen sensitive constituents, especially probiotic culture (98).
On the other hand, freeze-drying is an alternative to spray-drying for probiotics that are
sensitive to heat or oxygen. The lyophilization procedure produces a vaccum-drying condition
under very low temperature, which significantly preserves viability of microorganism during
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process. The process is beneficial for oxygen sensitive strains whose viability would be
dramatically damaged during spray-drying. However, commercial application of freeze-drying is
limited due to its higher cost and longer processing time when compared to spray-drying (99).
Extrusion is another encapsulation technology which is less hazardous when compared to
spray-drying. It is a procedure of producing small droplets of an encapsulated material using
pressure to force solution through openings in droplet-generating device or nozzles. The size of
droplets depends on diameter of openings or nozzle. This technology is relatively gentle and it
could be operated under aerobic or anaerobic environment (92). Syringe-extrusion is one of the
common used process, which is typically used to produce alginate beads. An alginate solution
containing bioactive core is extruded in calcium chloride solution to form droplets (99). For the
basic protection against acidity, alginate beads have been proven to maintain viability throughout
GIT and can be suitable for long-term storage (100).
There is no study showing evidence regarding the tolerability of A. muciniphila to high
level of acid and bile salt. In current study, the first objective was to investigate the survival rate
of A. muciniphila under stressed environment. The second objective was to evaluate the best
encapsulation methods to preserve the viability of A. muciniphila; in addition, the ability of
encapsulation in protecting the bioactivity of A. muciniphila was further investigated using a
simulated digestion method. It was hypothesized that a significantly improved viability would be
observed using encapsulation method when compared to delivering probiotics with no protection.
Methods
Acid tolerance
A. muciniphila cells were harvested by centrifugation and were washed three times using
PBS. Washed pellet was suspended with 1 mL of BHI. Fresh simulated gastric solution was
prepared daily by mixing 3 g/L pepsin in 0.9% w/v saline, and the pH was adjusted to 2.0. The
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suspended A. muciniphila was mixed with 5 mL of simulated gastric solution and 1.5 mL of 0.9%
w/v saline (87). The mixture was incubated at 37 °C for 3 hours, during which 0.1 mL aliquots
were drawn to determine viability at constant intervals of 0, 1, 2 and 3 hours.
Bile salts tolerance
Bile salt medium was prepared by suspending 0.3% w/v bile salts (LP0055 OXOID,
Ontario, Canada) in BHI medium. A. muciniphila cells were harvested by centrifugation and were
washed twice using 0.9% saline (87). Washed pellet was suspended in 1 mL bile salt medium and
inoculated into bile broth and incubated at 37 °C for 3 hours, during which 0.1 mL aliquots were
drawn to determine viability at constant intervals of 0, 1, 2 and 3 hours.
Spray-drying
A. muciniphila culture was centrifuged to form A. muciniphila pellet, which was suspended
with PBS to prepare for spray-dry. The Yamato GB210A spray dryer (Yamato Scientific America,
Santa Clara, CA) was used in current study. Inlet temperature was set to 120 °C and outlet
temperature was 55 – 60 °C. Speed was controlled at 1.75 mL/min, and pressure was 0.15-0.20
Mpa. Dried A. muciniphila powder was sprayed into the collector and then stored in 50 mL tubes
at – 20 °C for testing. Viability of A. muciniphila stock prepared for spray-drying and viability of
spray-dried A. muciniphila powder were compared using pour-plating method to evaluate the loss
of cell viability during spray-drying procedure. All samples were tested in duplicates.
Freeze-drying
A. muciniphila culture was centrifuged to form A. muciniphila pellet, which was suspended
with sterile 10% sucrose BHI solution in 50 mL tube to prepare for freeze-dry. The A. muciniphila
and sucrose BHI mixture was flash frozen with liquid nitrogen and stored at – 80 °C overnight. In
the next day, the 50 mL tube was uncapped, sealed with gauze and was freeze-dried for 48 hours
using FreeZone Triad Freeze Dryer (Labconco, Kansas City, MO). Freeze-dried A. muciniphila
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was gently grinded into powder and stored in – 20 °C freezer. Viability of A. muciniphila stock
prepared prior to freeze-drying and viability of freeze-dried A. muciniphila powder were compared
by pour-plating method to evaluate the loss of cell viability during freeze-drying procedure. All
samples were tested in duplicate.
Extrusion
Freeze-dried A. muciniphila powder was dissolved in 1% sterile sodium alginate solution
(Sigma-Aldrich, St. Louis, MO) at 5% (w/v). A homogenizer (IKA-labortechnik, Wilmington, NC)
was used to homogenize A. muciniphila powder with the solution. Once the mixture was fully
homogenized, it was transferred into a 60 mL syringe with a 22 G needle to extrude droplets into
sterile 0.1 M CaCl2 solution (Thermo Fisher Scientific, Ann Arbor, MI). Droplets of A. muciniphila
formed solid sphere beads after a 30-minute swirl in the CaCl2 solution. All the beads were drained
from the solution and washed twice with sterile deionized water to get rid of excessive solution.
Washed beads were dehydrated in the dehydrator (Excalibur, Sacramento, CA) at room
temperature for 48 hours, and stored at room temperature after fully dehydrated. Viability of A.
muciniphila stock prepared for extrusion and viability of dehydratedd A. muciniphila beads were
compared using pour-plating method to evaluate the loss of cell viability during extrusion
procedure. All samples were duplicated in the test.
Extrusion efficacy test
The efficacy of encapsulated A. muciniphila beads was evaluated using simulated
gastrointestinal digestion fluids to investigate the protective effect of encapsulation on viabilities.
PBS with 3 mg/mL pepsin (Sigma, St Louis, MO) was adjusted to pH 2 and enteric digestion fluid
(EDF) were used to simulate pH and digestive enzymes as human GIT. EDF was prepared with
the following formula: 0.4% w/v pancreatin (Sigma, St Louis, MO), 1.5% w/v bile salt (LP0055
OXOID, Ontario, Canada), 0.5% w/v amylase (Sigma, St Louis, MO), 0.1% w/v trypsin (Sigma,
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St Louis, MO), and 0.5% w/v lipase (Sigma, St Louis, MO) (81). A. muciniphila beads were
weighed first and then added into pepsin-PBS for an incubation of 1 hour at 37 °C. All liquid was
discarded after incubation. Then EDF was added and incubated with A. muciniphila beads at 37 °C
for 1.5 hours. After incubation, A. muciniphila beads were drained from excessive liquid and
washed with sterile deionized water. Washed A. muciniphila beads were added into sterile PBS
and homogenized. Serial dilution and pour-plating method were used to test the viability of beads.
At the same time, the same amount of original A. muciniphila beads were processed with same
procedure and tested for viability as untreated control.
Statistics
Data were expressed as mean ± SD. Statistical analysis was performed using one-way
analysis of variance (ANOVA) with a Tukey post-hoc test using GraphPad Prism version 6.00 for
Windows (GraphPad Software, San Diego, CA). Results were considered statistically significant
at p < 0.05.
Results
Figure 16 showed the effects of low pH and pepsin on viability of A. muciniphila. It was
clear that A. muciniphila was intolerant to this stressed condition. One hour of incubation resulted
in loss of 3.7 Logs of CFU (p < 0.0001), while in the following two-hour incubation, the cell
viability was maintained at a relatively stable status with no significant difference in the following
hours.
The tolerance ability of A. muciniphila to bile salts was presented in Figure 17. A.
muciniphila was observed with a significant decreased level of viability (1 Log number) within
the first hour (p < 0.0001). The viability was maintained at a similar level with no significant
difference in the following two hours.
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Table 2 listed the loss of viabilities after the procedure of encapsulation. Freeze-drying
method showed the minimal loss of cell viability and extrusion method presented an intermediate
preservation. Among three methods evaluated, viability of A. muciniphila had the most loss during
the procedure of spray-drying. Consequently, freeze-drying and extrusion methods were selected
for testing protection efficacy through simulated GIT. The results noted that freeze-dried A.
muciniphila without protection encountered a tremendous decrease of viability while extruded
beads were able to maintain A. muciniphila viability to the maximum level with barely no loss.
Discussion
The significant loss of CFU in both simulated stomach and proximal intestinal conditions
indicated that A. muciniphila was not able to survive through acidic environment as in a stomach.
This finding was consistent with previous test in exploring optimal pH for promoting growth of A.
muciniphila, which reported that A. muciniphila was sensitive to low pH level (pH < 5) and was
not able to survive. When testing its tolerance to bile salt, there was only 1 Log number of decrease
found in its cell viability, which suggested that A. muciniphila had better tolerance to bile salts
when compared to acids. The previous data reported that A. muciniphila showed a good BSH
activity, which helped with bile salts deconjugation and elimination of the detergent effect of bile
salts on A. muciniphila. In conclusion, it was necessary to provide additional protection for A.
muciniphila in order to guarantee sufficient and viable cells through human GIT.
The determination of proper encapsulation method is extremely critical for incorporating
probiotics in food products with adequate amount of living cells. In this study, three widely used
encapsulation methods were tested to determine the optimal vehicle for protection and the potential
delivery of A. muciniphila. The results showed consistency as hypothesized that freeze-drying
method maintained the highest viability of A. muciniphila while extrusion method showed an
higher viability loss, which was possibly due to steps as washing, drying and dehydration
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additional to the steps of freeze-drying. The largest viability loss during spray-drying process
might be caused by high temperature and potential air exposure. Although spray-drying is the most
time and cost saving method among the three options, result in this study suggested that spraydrying would not be a proper encapsulation method for processing A. muciniphila especially in
large quantity production. Based on this comparison, freeze-drying and extrusion were reliable
encapsulation methods to minimize the loss of A. muciniphila cells during process. The next step
was to test the efficacy of freeze-drying and extrusion in protecting A. muciniphila from low pH
and enzyme activities through simulated gastrointestinal digestion. The results showed that A.
muciniphila beads produced from extrusion method were effective in maintaining viabilities under
simulated stressed environment. The minimal loss in CFU has proved that A. muciniphila beads
could highly preserve the cell viability while the coating served anti-acid and non-enzymatic
reactive purposes. In comparison, the huge viability loss in freeze-dried A. muciniphila powder
indicated that A. muciniphila cells barely survived with sucrose solution as the only coating
material. In conclusion, extrusion would be the best encapsulation technique that could be used to
incorporate A. muciniphila in food product to minimize cell loss during processing and GIT
digestion. This efficient protection could guarantee bioaccessibility and bioavailability of A.
muciniphila for subsequent beneficial function in GIT.
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4.

LONG-TERM

DIETARY

EFFECTS

OF

A.

MUCINIPHILA

SUPPLEMENTATION ON HIGH-FAT INDUCED OBESITY AND DIABETES
In-vivo study is useful to better understand the effect of gut microbiota on health and
disease. Various studies have been focused on individual biomarkers or key attributes for certain
adverse physiological conditions (101); however, very few studies suggested any longer-term
effect for A. muciniphila administration in an obese mouse model. Current study was designed to
attempt to evaluate weight loss potential and glycemic control, and to observe possible sustainable
effects of A. muciniphila supplementation over a significantly longer period in a diet-induced
obese mouse model. It was hypothesized that supplementation of A. muciniphila for six months
would decrease body weight gain and improve glucose homeostasis. Mouse body weight was
monitored regularly in this study; additionally, individual mouse body composition was measured
at the end of the study to further investigate the effects of long-term A. muciniphila
supplementation. Glucose homeostasis was also evaluated to understand the effect of A.
muciniphila on parameters including fasting blood glucose, glucose tolerance and insulin
resistance. It was intended to further explore the potential anti-obesity mechanism of A.
muciniphila. Energy balance including food intake, fecal energy loss and basal energy expenditure
were measured to provide valuable information on energy absorption and metabolism. In addition,
supplementation safety of A. muciniphila oral administration was evaluated for the intention of its
future potential human study and food product development as a probiotic additive. The results
achieved from this mouse study would be informative and inspiring for future investigation of A.
muciniphila in clinical studies.
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Methods
Experimental animals
6-8 week old male C57BL/6 mice (Charles River Laboratoreis, Wilmingtong, MA) were
housed in Biological Science Building within a controlled environment: 12-hr day/night cycle,
room temperature kept at 72 - 77 °F, and moisture of 35 - 40%. Mice were randomly grouped as
six mice per cage with food and water ad libitum. Sani-chip bedding was provided in each cage to
avoid possible consumption of bedding materials. Upon reception, mice were acclimated for three
days with control diets. Grouped mice were assigned to three groups of 12 including control diet
(CD), high-fat diet (HF) and A. muciniphila supplemented high-fat diet (A. m). The energy content
of CD diet was 3.85 kcal/gram, which contained 10% of calories from fat and 70% from
carbohydrate (D12450J, Research Diets Inc, New Brunswick, NJ). The HF diet had 5.24 kcal/gram,
with 60% energy from fat and 20% from carbohydrates (D12492M, Research Diets Inc, New
Brunswick, NJ). All diets were stored at 4 °C until use. Mice in group A. m had daily oral
administration of A. muciniphila solution with a CFU of approximately 1010. A. muciniphila
solution was prepared daily by washing frozen A. muciniphila glycerol stock twice with sterile
water for the purpose of getting rid of any excess storage media solution with glycerol. The final
A. muciniphila culture pellet was resuspended in sterile water and fed to mice within 30 min after
preparation via gavaging. Mice in group CD and HF were orally administered daily with equivalent
volume of sterile water. Treatments lasted for six months. Food intake and body weight were
recorded weekly. Mice in groups HF and A. m were transferred to Wayne State University iBio
facility in the fifth month of treatment. After three-weeks’ stay in iBio facility, mice returned to
Biological Science Building.
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Glucose homeostasis analysis
Fasting glucose was measured monthly and the last measurement was performed prior to
sacrifice. In each of the monthly blood collection, mice were fasted for six hours with only water
provided. Mouse was restrained in the restraining device with the tail exposed. A small drop of
blood was obtained from the tail vein and placed on the test strip of blood glucose meter. Accucheck glucometer was used in this study (Roche, Indianapolis, IN).
Glucose tolerance test was performed in the fifth month of treatment. Glucose solution
(10%) was prepared and subsequently filtration sterilizated using a 0.2 μm syringe filter. Following
the same fasting procedure as above, fasting blood glucose of each mouse was measured as the
first time point. Each mouse was then gavaged with a glucose solution with a dose of 2 mg/g of
body weight. Blood glucose levels of each mouse were measured at 15, 30, 60 and 120 minutes
time points. Areas under the curve were calculated using standard trapezoid method (102).
Fecal energy test
Fecal samples were collected in the fifth month of treatment. Fecal pieces from each
individual cage were collected for a 24-hour period with food and water provided. Samples were
air-dried and stored in - 20 °C for further analysis. Bomb Calorimeter (Parr, Moline, IL) was used
to measure fecal energy content. In order to produce sufficient energy output, duplicated fecal
samples of 0.5 g each from each cage was weighed and burnt in the calorimeter to measure energy
released from the samples by measuring the quantity of heat produced. The fecal energy (kcal/g)
was calculated based on the actual amount of fecal content combusted, which was pre-test fecal
sample weight with post-test non-combustible residue weight subtracted. In addition, fecal energy
output/ energy intake ratio was calculated using the following formula: output ratio = total feces
energy/ total energy intake  100%.
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Body composition analysis (BCA) and energy expenditure analysis
Mice of group HF and A. m were transferred to Wayne State University iBio facility at the
end of fifth month. After a three-day acclimation, lean mass and fat mass of each mouse were
determined using EchoMRI-100 analyzer (EchoMRI, Houston, TX). Mouse was placed in the
holder tube without anesthetization, and the holder was inserted into the MRI analyzer. It took 2 3 minutes to finish the measurement of one mouse. In this study, each mouse was measured
consecutively three times to minimize free water error during measurement.
After BCA was performed, each mouse in groups HF and A. m was caged individually for
five days in TSE PhenoMaster home cage system (TSE systems, Chesterfield, MO). Activity level
of each mouse was measured by light beam interruptions recorded by activity monitor embedded
in the metabolic cage. Records were generated automatically to report the accumulation of distance
travelled.
Blood collection and serum sample preparation
After each mouse was euthanized by CO2 exposure, approximately 1 to 1.5 mL of blood
was collected from each mouse using heart puncture method. Cervical dislocation was performed
afterwards to make sure mouse was deceased. The blood sample collected was transferred into a
1.5 mL microtube and left undisturbed at room temperature for approximately 30 min. Blood
samples were then centrifuged at 1000 g for 10 minutes at 4 °C and the resulting supernatant was
aliquoted immediately into microtubes for different tests in order to avoid freeze-thaw cycles. All
microtubes were stored in a - 80 °C freezer for future testing. Any hemolyzed samples were
excluded from all tests.
Homeostatic model assessment of insulin resistance (HOMA-IR)
Fasting insulin was measured as manufacturer instructed using Ultra sensitive mouse
insulin ELISA kit (#90080 Crystal Chem, Doners Grove, IL). OD values were measured within
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30 minutes using plate reader at 450 nm and 630 nm. Insulin standard curve was generated to
quantify sample fasting insulin levels. OD values of mouse serum samples were interpolated using
the mean absorbance value of each sample and the standard curve. Fasting glucose and fasting
insulin results were used to calculate HOMA-IR using the following equation: HOMA-IR = 26 x
fasting glucose level (mg/dL) x fasting insulin level (ng/mL) / 405 (103).
Toxicity evaluation
Serum alanine transaminase Assay
Serum alanine transaminase (ALT) concentration was measured as manufacturer instructed
using ALT assay kit (#EALT-100, BioAssay Systems, Hayward, CA). OD values were measured
at 5 minutes and 10 minutes at 340 nm. ALT activity was determined using the equation:
𝐴𝐿𝑇 (𝑈/𝐿) = 381 ×

∆OD𝑆 −∆OD𝑁𝐴𝐷𝐻
𝑂𝐷𝑆𝑇𝐷 −𝑂𝐷𝐵𝐿𝐾

. ∆ODS was calculated by subtracting each sample OD at 10

minutes from the OD at 5 minutes. ∆ODNADH was calculated by subtracting NADH standard OD
at 10 minutes from the OD at 5 minutes. ODSTD and ODBLK were OD values of NADH standard
and blank at 340 nm at 5 minutes.
Aspartate transaminase assay
Serum aspartate transaminase (AST) concentration was measured as manufacturer
instructed using AST assay kit (#EASTR-100, BioAssay Systems, Hayward, CA). OD values were
measured at 5 minutes and 10 minutes at 340 nm. ALT activity was determined using the equation:
𝐴𝑆𝑇 (𝑈/𝐿) = 388 ×

∆OD𝑆 −∆OD𝑁𝐴𝐷𝐻
𝑂𝐷𝑆𝑇𝐷 −𝑂𝐷𝐵𝐿𝐾

. ∆ODS was calculated by subtracting each sample OD at 10

minutes from the OD at 5 minutes. ∆ODNADH was calculated by subtracting NADH standard OD
at 10min from the OD at 5 minutes. ODSTD and ODBLK were OD values of NADH standard and
blank at 340 nm at 5 minutes.
γ-Glutamyltransferase activity assay
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Serum γ-Glutamyltransferase (GGT) activity was measured as manufacturer instructed
using GGT activity calorimetric assay kit (MAK089 Sigma-Aldrich, St. Louis, MO). OD values
were measured every 5 minutes when incubated at 37 °C until the OD value was greater than the
OD value of the highest standard concentration. The final measurement (A418) final for calculating
the enzyme activity was the penultimate reading and the time of the penultimate reading was T final.
The first step of calculations was to establish a standard curve with initial measurement of pNA
standards. Change in measurement from Tinitial to Tfinal was calculated as ∆A418= (A418) final - (A418)
initial,

which was compared to the standard curve to determine the amount of pNA generated (B)

between Tinitial and Tfinal. GGT activity was determined using the equation: 𝐺𝐺𝑇 (𝑚𝑈/𝑚𝐿) =
𝐵 × 𝑠𝑎𝑚𝑝𝑙𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
,
(𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒) × 𝑠𝑎𝑚𝑝𝑙𝑒 𝑣𝑜𝑙𝑢𝑚𝑒

reaction time = Tfinal - Tinitial.

Blood urea nitrogen assay
Urea concentration in blood was measured as manufacturer instructed using QuantiChrom
urea assay kit (DIUR-100 BioAssay Systems, Hayward, CA). OD values were measured at 520
nm and the urea concentration was determined
𝑂𝐷𝑆𝑎𝑚𝑝𝑙𝑒 −𝑂𝐷𝐵𝑙𝑎𝑛𝑘
𝑂𝐷𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 −𝑂𝐷𝐵𝑙𝑎𝑛𝑘

the equation: [𝑈𝑟𝑒𝑎] (𝑚𝑔/𝑑𝐿) =

× 𝑛 × [𝑆𝑇𝐷], n was the dilution factor, [STD] was 50. Conversion of BUN

and Urea was: BUN (mg/dL) = [Urea]/ 2.14.
C-reactive protein assay
C-reactive protein concentration was measured as manufacturer instructed using Mouse Creactive protein (CRP) ELISA kit (#80634 Crystal Chem, Elk Grove Village, IL). The final OD
values were measured within 30 minutes at 450 nm and 630 nm. CRP calibration curve was plotted
using OD values and their corresponding CRP concentrations. The CRP concentration of serum
sample was interpolated using the calibration curve and mean OD value of each sample.
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Statistics
Data were expressed as mean ± SD. Statistical analysis was performed using one-way
analysis of variance (ANOVA) with a Tukey post-hoc test using GraphPad Prism version 6.00 for
Windows (GraphPad Software, San Diego, CA) after a significant difference was identified by
ANOVA. Results were considered statistically significant at p < 0.05.
Results
After six months of treatment, body weight trends of the three groups were presented in
Figure 18. The rate of body weight gain of CD group was the slowest, in which CD mice gained
about 8 g in the last thirty days. The group with the fastest gaining trend was HF group, and A. m
group showed a body weight gain between CD and HF groups, which had a rate of weight gain
faster than CD but slower than HF. The weight gain in A. m group was not significantly different
from weight gain in HF group, except a significant lower level of weight gain in A.m group was
observed within a period of 26 days (day 46 to day 72) when compared to HF group (p < 0.05).
Food intake of grouped mice was measured every week. Food intake of CD group was
significantly higher than that of HF and A. m groups (p< 0.01), while no significant difference was
found between HF and A. m groups (Figure 19). Energy intakes were calculated based on the
caloric content in foods, which was 3.9 kcal/g for CD diet and 5.2 kcal/g for HF/A. m diet. During
six-month of treatment, mice in CD, HF and A. m groups consumed similar level of energy with
no significant difference among the three groups (Figure 20).
Fasting blood glucose of each mouse was measured on monthly basis, which corresponding
to first, second, fourth, fifth and sixth month. Figure 21 clearly pictured that fasting blood glucose
of HF group mice was at the highest level among the three groups with a peak at 232 ±39 mg/dL
after four months of treatment. It was noted that CD and A. m group had relatively stable fasting
blood glucose during all six months. There was no significant difference found between CD and

42
A. m group during all six months treatment except for the third month (p < 0.05); however, mice
in HF group showed significantly higher fasting blood glucose when compared to CD group along
the treatment period (p < 0.01).
In addition, all three groups of mice were tested for glucose tolerance as well. Blood
glucose levels were measured at time points of 0, 15, 30, 60, and 120 minutes (Figure 22). Baseline
glucose started at a similar level across groups; however, significant difference were observed after
15 minutes when HF group showed higher blood glucose levels as compared to both CD and A.
m groups. The blood glucose of CD and A. m groups decreased to baseline level 60 minutes after
glucose intake. This was not observed in HF group, where average blood glucose level was
decreasing very gradually in a span of 120 minutes before returning to baseline level. HF group
reached to the peak at 15 minutes time point, when A. m group showed a significantly lower level
(p < 0.001). After another 15 minutes, no obvious decrease was found in HF group while A. m
group had a significant drop of blood glucose (p < 0.0001). At the 60-minute time point, blood
glucose level of HF group slowly decreased, which was still significantly higher than the level of
A. m group (p < 0.001). At the end of 120 minutes, A. m group showed the lowest blood glucose
when HF showed a significantly higher level (p < 0.001).
Subsequently, area under curve (AUC) based on the results of glucose levels in GTT was
calculated, which is depicted in Figure 23. Significant difference was discovered in AUC among
CD, HF and A. m groups. HF group was shown with a significantly higher level of AUC when
compared to CD and A. m groups (p < 0.0001) while there was no significant difference between
CD and A. m groups. Fasting insulin and glucose at month six were used to calculate HOMA-IR.
Insulin results showed that while CD and HF groups had the lowest and highest respectively, there
was no significant difference among CD, HF and A. m groups (Table 3). Fasting blood glucose of
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HF group was shown significantly higher than that of the CD group (p < 0.01). The calculation of
HOMA-IR confirmed that HF group had a significantly higher level when compared to CD group
(p < 0.01) while no difference was observed between A. m and CD groups.
Figure 24 compared the fecal energy content of the three groups. The results showed that
CD group had the highest and A. m group had a lower fecal energy content but no significant
difference between these two groups. HF group had the lowest fecal energy content, which was
significantly lower than CD group (p < 0.01). Figure 25 showed that group A. m and HF had
significantly higher fecal energy output ratio than that of the CD group (p < 0.05), while no
significant difference was observed between A. m and HF groups.
Body composition of mice in HF group and A. m group was measured after five months of
A. muciniphila administration. No significant difference was observed between HF and A. m
groups in both lean mass percentage and fat mass percentage. Data collected from metabolic cages
showed the distance travelled of each mouse accumulated in one day. HF group and A. m group
showed a similar level of average distance with no significant difference, which were 25431.7 
9387.4 cm/day per mouse and 23681.6  7181.2 cm/day per mouse respectively.
Safety of A. muciniphila administration was evaluated by measuring liver and kidney
toxicity. Serum AST, ALT and GGT of mice in CD, HF and A. m groups were compared and
presented in Table 5. No significant difference was noted among three groups in AST, ALT and
GGT as liver toxicity indicators. CD, HF and A. m groups showed a similar level of serum BUN
(p > 0.05) in kidney function test.
CRP levels of mice in three groups were tested at the end of 6-month treatment. Figure 26
showed that there were no differences among CD, HF and A. m groups.
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Discussion
In the beginning of this study, mice were randomly assigned to groups with control diet,
high-fat diet and high-fat diet with A. muciniphila administration. When comparing body weight
of mice in HF group and A. m group, it was obvious that mice treated with A. muciniphila had
lower body weight and slower body weight gain. These two groups started with no difference of
body weight gain in the first two months, while the difference gradually increased and became
significant after 46 days. However, the significance between HF and A. m groups disappeared
during the last three months of this study. This finding indicated that the supplementation of A.
muciniphila had ability to reduce body weight gain, but the benefit might be short-lived and may
be reversed by other factors. Schneeberger et al. reported that abundance of A. muciniphila in DIO
mice decreased significantly with time. The HF diet lowered A. muciniphila population by about
10,000 folds than its initial population. In addition, A. muciniphila population also had a decrease
of 100 folds in mice fed with CD diet for 4 months (104). Thus, it was hypothesized that population
of A. muciniphila in GIT reduced slowly with time. Furthermore, a diet with high fat level damaged
A. muciniphila abundance even more. Aging may be another factor that affected the abundance as
well. When A. muciniphila was first fed to the mice, it had a consistent viability of 109 CFU, which
could be enough to induce beneficial effects to control body weight gain in mice; however, the
benefits were reduced because this viability was not sufficient enough to compensate for the
significant loss of A. muciniphila abundance induced by long-term high fat feeding and aging. As
a result, it suggested the dosage of A. muciniphila is highly important in delivering and preserving
the benefits of A. muciniphila to the host. Moreover, it was found that mice had varied responses
when supplemented with A. muciniphila. The body weight gain in A. m group had large variation:
the lowest body weight gain was 16.54 g while the highest was 30.06 g. Therefore, it indicated
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that the effect of probiotic supplementation varied individually and other genetic or environmental
factors may play a role in determining the beneficial effects of probiotic supplementation.
Food intakes (grams) of grouped mice showed that mice in HF and A. m groups were
similar, which suggested that A. muciniphila had no influence on mice’s appetite for food. After
further calculation of calories intake, it was shown that mice in CD, HF and A. m groups consumed
similar calories each day. These results suggested that mice did not adjust the energy content of
food by consuming less volume of HF food, and HF intake was not affected by A. muciniphila
consumption.
Mice in CD group had the lowest level of blood glucose while mice in A. m group presented
lower values when compared to mice in HF group during the whole period of treatment.
Additionally, blood glucose responses in GTT demonstrated the ability of A. m to improve glucose
tolerance and consequently bring blood glucose back to normal level. This result supported the
findings reported by Everard et al. (78). The improvement was further confirmed by calculation of
AUC based on glucose tolerance test results. AUC of A. m group was similar to that of the CD
group, while AUC of HF group was at a significantly higher level comparing to both CD and A.
m groups. Inspired by this significant difference of AUC between A. m and HF groups, HOMAIR was calculated by using fasting insulin and fasting blood glucose values. HOMA-IR of HF
group was significantly higher than CD group while the significance was diminished after
supplementation of A. muciniphila for six months. In conclusion, the administration of A. m was
able to lower fasting blood glucose and reduce insulin resistance when compared to HF group. An
increase of A. muciniphila dosage might be able to further improve on blood glucose, insulin levels
and reduce insulin resistance.
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Fecal energy output, body composition, and activity levels were analyzed to evaluate the
possible beneficial effects of A. muciniphila treatment. It was expected to see higher fecal energy
content from mice in A. m group. However, the calculated energy per gram of fecal sample only
showed a difference between CD and HF group. Therefore, the energy intake/ output ratio was
determined as a better expression of actual energy utilization. Results revealed a significant
difference between CD and both HF and A. m groups, but A. m and HF groups were not different.
The trend of higher output ratio in A. m group could indicate the effect of A. m in altering energy
absorption and excretion. However, it was suspected that 24hr fecal sample may not be sufficient
to obtain a statistical significance in fecal energy measurement. In addition, mouse fecal pieces
were collected per cage instead of individually, which might have contributed to inaccurate
representation of output ratio for each mouse based on intake. Further collection of larger quantity
of fecal sample, such as 48-hr samples collection, from each mouse individually could provide a
better estimate of fecal energy output.
In order to investigate whether A. muciniphila administration with a HF diet would
positively affect body composition, body composition of mice in HF and A. m groups were
measured at the fifth month of treatment using echo MRI machine. The similar percentage of lean
and fat content between HF and A. m groups indicated that the administration of A. muciniphila
was not able to alter mouse body composition. Energy expenditure of mice were measured using
metabolic cages during the fifth month of treatment. The metabolic cages were able to record the
activity level in term of distance traveled of each mouse throughout housing period, which
provided more information regarding whether activity level could correlate with different
treatment in an indirect manner. Results indicated that mice in A. m group had a non-significantly
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lower level of daily physical activity when compared to mice in HF group. However, the 2000 cm
per day difference could form into a significant difference after a long-term treatment of A. m.
Evaluating the safety of A. m consumption on animal models is crucial for establishing
safe administration in human consumers. At the end of 6-month treatment, liver and kidney
toxicity biomarkers AST, ALT, GTT and BUN were measured to ensure safety and any possible
unknown adverse reaction (105-107). The results showed that mice fed with control diet, high-fat
diet and A. m fortified high-fat diet had no significant differences in AST, ALT and GTT
concentrations, and no difference was found in BUN concentration as a kidney function parameter
as well. These results demonstrated the safety of A. muciniphila consumption at the concentration
administered to mice. Whether this concentration is also safe for human consumption requires
further study with humans.
CRP level is associated with insulin resistance (108) and diabetes mellitus (109). In insulinresistant obese individuals, the elevated CRP level parallel with insulin resistance and reduction
in CRP level is associated with weight loss, but independent of body mass (110). The concentration
of CRP is also considered as an important nonspecific biochemical marker for inflammation, thus
CRP has been used as an indicator for the development of chronic diseases and for monitoring
responses to treatment for inflammation and infection (111). Results in this study indicated that
there was no significant difference among the three groups. Additional tests with higher
concentration of A. muciniphila administration or for a longer period of time is warranted to further
investigate the inflammation conditions.
Conclusion
The current study demonstrated that there were beneficial effects of A. muciniphila
administration on glucose homeostasis on high fat induced obesity. With six months feeding of a
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HF diet with added A. muciniphila intervention, there was no alteration of body weight and body
composition, although there was a significant effect on reduced body weight gain at the earlier
stage of treatment. The diminishing effect was clearly observed as mice aged and consumed high
fat diet continuously. This led to a speculation that aging and high fat feeding had more negative
effects than what A. muciniphila could improve with current dosage. The most consistent effect
was observed in improving fasting blood glucose and glucose tolerance. A. m group had lower
average levels of these parameters when compare to HF group in a consistent manner. It was
demonstrated that A. muciniphila could maintain the long-term sustainable effect of improving
glucose tolerance as oppose to the suppression of weight gain at the end of sixth month.
Furthermore, GTT test and HOMA-IR as indicators for pancreatic function, did show significant
improvement in A. muciniphila treated group, which had similar observation as low fat diet control
group. This further shows plausible long-term effect on improving glucose homeostasis by A.
muciniphila. In addition, the safety of A. muciniphila supplementation to the mice at current
concentration has been demonstrated in this study. These results would provide guidelines to future
studies with human subjects.
Future direction
In current study, the administration of A. muciniphila showed a slower weight gain trend
when compared to HF group, even though a significant difference was only maintained for
approximately one month. For future studies, energy intake and exertion, physical activity levels
and basal metabolic rate during the time when body weight difference is significant should be
measured in order to identify the factors that contribute to the difference. There were evidences
showing a dramatic decrease of A. muciniphila population associated with high fat feeding and
aging; therefore, future study should modify the dosage or frequency of A. muciniphila
supplementation. The dosage might be adjusted depending on the on-set of body weight gain and
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age in order to reverse the loss of A. muciniphila in the host gut. This dosage information may be
extrapolated to human studies before a recommendation for human supplementation can be
reached.
Based on energy expenditure recorded in metabolic cages, mice in A. m group had lower
activity level when compared to mice in HF group regarding their distance travelled in 24 hours.
When less physical activity was accumulated for months, it might diminish the benefits of A.
muciniphila consumption. This might be one of the factors contributed to the disappearance of
significant difference of body weight between the two groups and similar body composition during
the later period of treatment. If mice in A. m group could increase their activity level to the level
of mice in HF group, it was spectulated that the effects of A. muciniphila would be more significant.
Thus, it is hypothesized that increasing physical activity could enhance the beneficial effects of
probiotic supplementation. This hypothesis should be examined in future studies. In addition, the
future use of metabolic cages for each individual mouse and for the entire study period could
provide information to reveal different reaction of individual mouse to probiotic supplementation,
including difference in food intake, energy expenditure and fecal energy content.
The next area to focus is regarding the formulation and delivery of strain A. muciniphila.
According to prebiotic screening test, it was clear that the incorporation of IMO as prebiotic
significantly promoted the growth of A. muciniphila. This finding could be used to adjust
formulation of potential A. muciniphila supplementation products. The mixture of IMO and A.
muciniphila could easily enhance its viability, which will be more cost-effective instead of
manufacturing A. muciniphila with high CFU. In addition, this strain requires additional
encapsulation in order to guarantee sufficient cell viability through GIT.
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Since the safety of consuming A. muciniphila for six months has been demonstrated, the
future study should evaluate the benefits of A. muciniphila supplementation in human subjects.
Human gut has different microbiome composition from research animals, and more environmental
factors could be involved in the balance of gut microbiome. Thus, clinical trials with human
volunteers are warranted to examine effects of probiotic intake on host health. Clinical studies on
A. muciniphila are still very limited. This study provided evidences that supplementation of A.
muciniphila may help with body weight control and better improvement on glucose homeostasis.
In future clinical studies, it is recommended to encapsulate A. muciniphila with IMO with
extrusion method to make sure minimal viability loss through GIT. The mechanism of A.
muciniphila affecting the host could be further studied using different targeted groups by
consuming A. muciniphila with customized dosages, such as obese individuals, patients with T2D
or patients with metabolic syndrome. The possible interactions of A. muciniphila with microbiome
of the host could be further analyzed, such as comparing the alteration of gut microbiome,
screening strains or metabolites for possible symbiotic effects, evaluating benefits of weight
management through energy balance, lipid metabolism and nutrient harvest, investigating benefits
of insulin and glucose homeostasis, analyzing improvement on gut barrier function such as
intestinal permeability and metabolic endotoxemia.
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FIGURES AND TABLES
Table 1. Quantitative determination of BSH activity of five selected probiotic strains
Probiotic strain

Total protein (μg/mL)

Total activity (U/g total protein)

A. muciniphila

356.5 ±24.8

32.3 ±4.7cooo

L. acidophilus

334.5 ±48.0

33.9 ±4.2coo

L.reuteri

364.0 ±33.8

143.6 ±7.4a

L. plantarum

351.5 ±69.0

96.3 ±15.2b

B. coagulans

376.1 ±61.0

20.9 ±4.0c

(Values with different letters were significantly different from each other at p < 0.001, p < 0.01,
or p < 0.05.)
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Table 2. Loss of viability after encapsulation procedure and bypass simulated GIT
Loss during encapsulation

Loss bypass GIT

Spray-dried

Freeze-dried

Extruded

Freeze-dried

Extruded

2.58  0.20 Logs

0.32  0.03 Logs

1.13  0.03 Logs

4.75  0.02 Logs

0.10  0.03 Logs

53
Table 3. HOMA-IR of groups CD, HF and A. m after 6-month of treatment
Fasting blood glucose (mg/dL)

Fasting insulin (ng/mL)

HOMA-IR

CD

161.2 ±8.9a

2.2 ±0.8a

22.5 ±8.6a

HF

217.4 ±30.2b

4.6 ±1.1a

64.3 ±15.5b

A. m

177.2 ±12.9ab

3.9 ±2.0a*

44.5 ±22.7ab*

(Values in each column with different letters were significantly different from each other at p <
0.001, p < 0.01, or p < 0.05.)
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Table 4. Body composition of mice in groups HF and A. m
Fat (g)

Lean (g)

Fat (%)

Lean (%)

HF

21.8 ±2.0

22.9 ±2.2

45.1 ±3.6

47.9 ±4.6

A. m

21.3 ±2.9

21.5 ±2.0

45.3 ±2.8

46.0 ±2.6
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Table 5. Safety of A. muciniphila administration by evaluating liver and kidney toxicity
Liver

Kidney

AST (U/L)

ALT (U/L)

GGT (U/L)

BUN (mg/dL)

CD

4.9 ±1.4

61.6 ±21.8

1.7 ±0.3

19.8 ±2.1

HF

9.6 ±5.6

42.6 ±40.9

1.7 ±0.9

26.3 ±5.3

A. m

6.4 ±3.5

78.4 ±14.7

1.7 ±0.4

21.3 ±1.6
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Figure 1. Turbidity standard curve determination. A. muciniphia cultures were incubated at
37 °C for 10 hrs, and final optical density (OD) values were measured at 595 nm using
spectrophotometer. Colony forming unit (CFU) was evaluated using pour-plating method at the
same time. The verification equation was established based on OD values and their corresponding
CFU/200 uL.
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Figure 2. Growth curves of A. muciniphila under various temperatures. Cultures with same
concentration of A. muciniphila were incubated for 10 hrs in incubators set with temperature at
25 °C, 35 °C, 37 °C, 40 °C, 43 °C and 46 °C. Final culture OD values were measured at 595 nm
at hourly interval.
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Figure 3. Effects of temperature on exponential growth rate of A. muciniphila. Cultures with
A. muciniphila were incubated at various temperatures for 10 hours.Bars with different letters were
significantly different from each other at p < 0.001, p < 0.01, or p < 0.05.
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Figure 4. Effects of temperature on final viabilities (CFU/mL) of A. muciniphila. Cultures
with A. muciniphila were incubated at various temperatures for 10 hours.Bars with different letters
were significantly different from each other at p < 0.001, p < 0.01, or p < 0.05.
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Figure 5. Growth curves of A. muciniphila at various pH levels. Tubes with medium adjusted
to pH level of 2, 3, 4, 5, 6, 6.5, 7, 7.5, 8, and 9 were inoculated with same concentration of A.
muciniphila. Cultures were incubated for 12 hrs at 37 °C and final culture OD values were
measured at 595 nm at hourly interval.
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Figure 6. Effects of pH levels on exponential growth rate of A. muciniphila. Cultures with A.
muciniphila were incubated at 37 °C for 12 hours Bars with different letters were significantly
different from each other at p < 0.001, p < 0.01, or p < 0.05.
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Figure 7. Final viabilities of A. muciniphila (CFU/mL) at various pH levels. Cultures with A.
muciniphila were incubated at 37 °C for 12 hours.Bars with different letters were significantly
different from each other at p < 0.001, p < 0.01, or p < 0.05.
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Figure 8. Growth curves of A. muciniphila in medium adjusted with prebiotics. Tubes with
medium adjusted by 0.2% w/v prebiotic ingredients including: isomaltooligosaccharide (IMO),
inulin (INU), fructooligosaccharide (FOS), galactooligosaccharide (GOS), guar gum (GG), acacia
gum (AG), karaya gum (KG), tragacanth gum (81), and potato starch (PS) were inoculated with
same concentration of A. muciniphila. Cultures were incubated for 10 hrs at 37 °C and final culture
OD values were measured at 595 nm at hourly interval.
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Figure 9. Effects of prebiotics on exponential growth rate of A. muciniphila. Cultures with A.
muciniphila were incubated at 37 °C for 10 hours. Bars with different letters were significantly
different from each other at p < 0.001, p < 0.01, or p < 0.05.
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Figure 10. Effects of prebiotics on final viabilities of A. muciniphila (CFU/mL). Cultures with
A. muciniphila were incubated at 37 °C for 10 hours. Bars with different letters were significantly
different from each other at p < 0.001, p < 0.01, or p < 0.05.
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Figure 11. Growth curves of A. muciniphila in medium adjusted with sugars. Tubes with
medium adjusted by 0.2% w/v sugars including: fructose (FRUC), galactose (GALAC), lactose
(LAC), sucrose (SUC), dextrose (DEX) and maltose (MAL) were inoculated with same
concentration of A. muciniphila. Cultures were incubated for 14 hrs at 37 °C and final culture OD
values were measured at 595 nm at hourly interval.
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Figure 12. Effects of sugars on growth rate of A. muciniphila. Cultures with A. muciniphila
were incubated at 37 °C for 14 hours. Bars with different letters were significantly different from
each other at p < 0.001, p < 0.01, or p < 0.05.
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Figure 13. Effects of sugars on final viabilities of A. muciniphila (CFU/mL). Cultures with A.
muciniphila were incubated at 37 °C for 14 hours.Bars with different letters were significantly
different from each other at p < 0.001, p < 0.01, or p < 0.05.
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Figure 14. Effects of sugar concentrations on viabilities of A. muciniphila (CFU/mL). Tubes
with medium adjusted by varied sugar concentrations including: 0.1%, 0.2%, 0.5%, 1.0% and 2.0%
were inoculated with same concentration of A. muciniphila. Cultures were incubated for 14 hrs at
37 °C and final culture OD values were measured at 595 nm at hourly interval. Bars with different
letters were significantly different from each other at p < 0.001, p < 0.01, or p < 0.05.
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Figure 15. Efficacy of storage method for A. muciniphila. A. muciniphila was collected from
culture medium, suspended and stored in 50% glycerol medium stored for 6 mons. Final CFU was
evaluated using pour-plating method.
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Figure 16. Acid tolerance ability of A. muciniphila. A. muciniphila was incubated in simulated
gastric solution at 37 °C for 3 hrs, and culture CFU was evaluated using pour-plating method at
hourly interval. Bars with different letters were significantly different from each other at p < 0.001,
p < 0.01, or p < 0.05.
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Figure 17. Bile salts tolerance ability of A. muciniphila. A. muciniphila was incubated in 0.3%
bile salts BHI medium at 37 °C for 3 hrs, and culture CFU was evaluated using pour-plating
method at hourly interval. Bars with different letters were significantly different from each other
at p < 0.001, p < 0.01, or p < 0.05.
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Figure 18. Mice body weight (gram) during 6-month of A. muciniphila administration.
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Figure 19. Average food intake (grams/mice) of all groups during 6-month treatment
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Figure 20. Average food intake (kcal/mice) of all groups during 6-month treatment
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Figure 21. Average fasting blood glucose (mg/dL) of all groups during 6-month treatment.
The 1st trial corresponded to the first month, the 2nd trial corresponded to the second month, the 3rd
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Figure 23. Area under curve (AUC) of glucose tolerance test in groups CD, HF and A. m.
Bars with different letters were significantly different from each other at p < 0.001, p < 0.01, or p
< 0.05.
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Figure 24. Fecal energy content (kcal/g) of groups CD, HF and A. m. Fecal energy content was
measured using Bomb Calorimeter. Each group included two cages, and each cage was measured
in duplicates. Bars with different letters were significantly different from each other at p < 0.001,
p < 0.01, or p < 0.05.
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Figure 25. Fecal energy output ratio (%) of groups CD, HF and A. m. Fecal energy output
ratio was calculated using formula: output ratio = total feces energy / total energy intake  100%.
Bars with different letters were significantly different from each other at p < 0.001, p < 0.01, or p
< 0.05.
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measured after 6-month of A. muciniphila administration
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ABSTRACT
THE EXPLORATION OF CHARACTERISTICS OF AKKERMANSIA MUCINIPHILA,
AND EVALUATION OF ITS PROBIOTIC EFFECTS ON DIABETES BY USING C57BL/6
MOUSE MODEL
by
JIANGQI TANG
December 2018
Advisor: Dr. Kai-Lin Catherine Jen
Major: Nutrition and food science
Degree: Doctor of Philosophy
The prevalence of type 2 diabetes (T2D) is increasing continuously worldwide. The
incidence of T2D is highly correlated with poor diet, physical inactivity and occurrence of obesity.
Recent studies reported possible interaction between T2D and gut microbiome, which revealed
different composition of gut microbiome. A specific strain Akkermansia muciniphila (A.
muciniphila) was reported with significantly lower abundance even prior to the incidence of
diabetes. This study was designed to discover the optimal growth conditions based on
characteristics of A. muciniphila and determine appropriate encapsulation method to ensure
sufficient bioactivity through GIT. C57BL/6 mice model was further used to explore in-vivo
benefits of A. muciniphila supplementation. Results showed medium adjusted to pH 6.5 could
promote the best growth of A. muciniphila at 37 °C. Isomaltooligosaccharide was proved to be the
best prebiotic ingredient. In order to manufacture in large quantity, fructose, sucrose and dextrose
were able to promote the highest viability, especially with the concentration of 0.5%. Bile salt
hydrolase activity was discovered in A. muciniphila with an intermediate level, which helped to
improve its tolerance to digestion system with high concentration of bile salts. Extruded beads of
A. muciniphila was shown to be an outstanding protection through simulated stomach and GIT.
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After diet induced mice were supplemented with A. muciniphila for six months, results showed no
significant change in mice body weight or daily food intake; however, improvement on glucose
homeostasis was noticed including fasting blood glucose and glucose tolerance. In addition, mice
supplemented with A. muciniphila showed a higher energy loss in feces while no difference was
found in energy expenditure or body composition. A. muciniphila has been proved to be safe after
a supplementation for six months. Future studies would investigate the benefits of A. muciniphila
with increased dosage and its possible mechanism in the host.

99
AUTOBIOGRAPHICAL STATEMENT
JIANGQI TANG
Education:
MS- Wayne State University, Nutrition and Food Science (2012-2014)
BS- Shanghai Normal University, Food Science and Engineering (2008-2012)
Professional Experience:
Graduate Teaching Assistant- Nutrition and Food Science 01/2015-05/2017. Wayne State
University, Detroit, MI
Nutritionist- Nutriease China 08/2014-12/2014. Wuxi, China
Instructional Assistant- Nutrition and Food Science 08/2013-12/2013. Wayne State University,
Detroit, MI
Conference:
Jiangqi T, Michael S, Yu-lyu Y, Jaipal S, K-L. Catherine J. Desk Jockey: A Device to Increase
Non-Exercise Activity Thermogenesis (NEAT) in Adults. Poster presentation at Experimental
Biology annual meeting. 04/2014. San Diego, CA

